Latest news with #LupinDiagnostics
&w=3840&q=100)
Business Standard
09-07-2025
- Business
- Business Standard
Lupin share pops 2% on licencing and supply agreement with Zentiva; details
Lupin share price: Pharmaceutical company Lupin share price rose as much as 2.30 per cent to hit an intraday high of ₹1,965.90 per share on Wednesday, July 9, 2025. Around 10:40 AM, Lupin share price continued to trade higher, up 1.14 per cent at 1,943.55 per share. In comparison, BSE Sensex was trading flat with a negative bias at 83,675.37 levels. Why did Lupin share price rise today? Lupin's share price rose in trade today after the company announced a licensing and supply agreement with Zentiva, k.s., for the commercialisation of its biosimilar Certolizumab Pegol. In an exchange filing, Lupin said, 'We hereby inform you that the company has entered into a License and Supply Agreement with Zentiva, k.s., for commercialisation of Lupin's biosimilar Certolizumab Pegol. Lupin said it has signed a deal with Zentiva under which it will develop, manufacture, and supply the biosimilar, while Zentiva will handle commercialisation in Europe and the CIS region, leveraging its strong regional infrastructure and regulatory capabilities. Lupin will retain commercialisation rights in other key markets, including the US and Canada. As part of the agreement, Zentiva will make non-refundable payments of up to $50 million to Lupin based on regulatory milestones, which includes an upfront payment of $10 million. Both companies will jointly invest in the biosimilar's development, and profits from defined markets will be shared. About Lupin Lupin is among the leading Indian multinational pharmaceutical companies headquartered in Mumbai, known for its expertise in developing and commercialising generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). With operations spanning over 100 countries, including key markets like the US, India, South Africa, and regions across Asia Pacific, Latin America, Europe, and the Middle East, Lupin has established itself as a global player. The company holds strong positions in therapeutic areas such as cardiovascular, diabetology, asthma, paediatrics, and central nervous system (CNS) disorders. Notably, it is also a global leader in anti-tuberculosis and cephalosporin segments. Founded in 1968 by Desh Bandhu Gupta with a mission to combat life-threatening infectious diseases, Lupin has grown into a pharmaceutical powerhouse with a robust global footprint. It operates multiple manufacturing facilities in India, including sites at Mandideep, Ankleshwar, Tarapur, and Vadodara, supported by a network of research centers and a large workforce. In addition to its pharmaceutical business, the company has expanded into diagnostics through its wholly owned subsidiary, Lupin Diagnostics, which operates a national reference laboratory in Navi Mumbai.
Business Upturn
23-04-2025
- Business
- Business Upturn
Lupin Diagnostics achieves 100% NABL accreditation for all greenfield labs
By Aditya Bhagchandani Published on April 23, 2025, 10:18 IST Lupin Diagnostics Limited, a wholly owned subsidiary of global pharmaceutical company Lupin, has announced that it has secured 100% NABL accreditation across all its greenfield laboratories in India. This makes Lupin Diagnostics one of the few diagnostic chains in the country to have all its facilities accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL). In a statement released on April 23, 2025, Ravindra Kumar, CEO of Lupin Diagnostics, said, 'This accreditation is a testament to the team's dedication to patient care and our mission to promote healthier lives. The 27 greenfield labs across the country ensure timely and accurate reporting. Our goal is to empower doctors and patients with evidence-based diagnostics.' The recognition reflects Lupin Diagnostics' consistent focus on quality, operational efficiency, and patient-centric services. The company has been recognized with several national awards, including the 'Patient-Centric Diagnostic Laboratories Company of the Year' at the IHW 3rd Patients First Award 2024, and 'Pathology Lab of the Year' at the ET Healthcare Awards 2022 and 2024. Founded in December 2021, Lupin Diagnostics started with a 45,000 sq. ft. National Reference Laboratory in Navi Mumbai and has since grown its footprint across West, South, East, and Central India. Its labs provide over 3,000 types of diagnostic tests, including molecular diagnostics, microbiology, cytology, immunology, and biochemistry. This milestone marks a significant step in Lupin's broader vision of enhancing healthcare infrastructure in India and promoting accurate, reliable, and accessible diagnostics to every corner of the country. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
